1. Home
  2. GEN vs VTRS Comparison

GEN vs VTRS Comparison

Compare GEN & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GEN
  • VTRS
  • Stock Information
  • Founded
  • GEN 1982
  • VTRS 1961
  • Country
  • GEN United States
  • VTRS United States
  • Employees
  • GEN N/A
  • VTRS N/A
  • Industry
  • GEN Computer Software: Prepackaged Software
  • VTRS Medicinal Chemicals and Botanical Products
  • Sector
  • GEN Technology
  • VTRS Health Care
  • Exchange
  • GEN Nasdaq
  • VTRS Nasdaq
  • Market Cap
  • GEN 16.7B
  • VTRS 15.6B
  • IPO Year
  • GEN N/A
  • VTRS N/A
  • Fundamental
  • Price
  • GEN $29.88
  • VTRS $13.25
  • Analyst Decision
  • GEN Buy
  • VTRS Hold
  • Analyst Count
  • GEN 5
  • VTRS 3
  • Target Price
  • GEN $27.80
  • VTRS $13.33
  • AVG Volume (30 Days)
  • GEN 3.5M
  • VTRS 7.7M
  • Earning Date
  • GEN 10-30-2024
  • VTRS 11-07-2024
  • Dividend Yield
  • GEN 1.67%
  • VTRS 3.62%
  • EPS Growth
  • GEN N/A
  • VTRS N/A
  • EPS
  • GEN 0.99
  • VTRS N/A
  • Revenue
  • GEN $3,863,000,000.00
  • VTRS $15,048,500,000.00
  • Revenue This Year
  • GEN $3.91
  • VTRS N/A
  • Revenue Next Year
  • GEN $3.36
  • VTRS N/A
  • P/E Ratio
  • GEN $30.24
  • VTRS N/A
  • Revenue Growth
  • GEN 2.44
  • VTRS N/A
  • 52 Week Low
  • GEN $19.08
  • VTRS $9.08
  • 52 Week High
  • GEN $30.89
  • VTRS $13.62
  • Technical
  • Relative Strength Index (RSI)
  • GEN 58.77
  • VTRS 67.70
  • Support Level
  • GEN $28.89
  • VTRS $12.53
  • Resistance Level
  • GEN $30.89
  • VTRS $13.09
  • Average True Range (ATR)
  • GEN 0.53
  • VTRS 0.44
  • MACD
  • GEN -0.06
  • VTRS 0.07
  • Stochastic Oscillator
  • GEN 48.91
  • VTRS 91.00

About GEN Gen Digital Inc.

Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: